Home / Therapies / SGLT-2 Therapy Center (page 5)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Little Known Benefit in Using SGLT2 Inhibitors

Dec 3, 2019 Paid, SGLT-2 Therapy Center

While the major impact of hypomagnesemia on cardiovascular outcomes and T2DM has been known, recent evidence suggests that SGLT2 inhibitors may normalize Mg2+ levels.

Canagliflozin’s Efficacy and Safety For Delaying and Possibly Preventing ESKD

Nov 23, 2019 Nephrology, SGLT-2 Therapy Center

Kidney failure is an enormous concern for people with T2D and DKD. This analysis confirms canagliflozin can slow its progression and have an impact on patients regardless of their level of kidney function.

Head-to-Head Comparison: Oral Semaglutide vs. Empagliflozin

Nov 23, 2019 GLP-1 Agonist Therapy Center, Paid, SGLT-2 Therapy Center

The first oral glucagon-like peptide receptor agonist recently gained FDA approval, but how does it compare to oral agents already on the market?

Fracture Risk and Sodium-Glucose Transport Inhibitors

Nov 19, 2019 Paid, SGLT-2 Therapy Center

Did the FDA make a mistake by labeling SGLT2 inhibitors as a fracture risk?

SGLT Inhibitors as Adjunct Therapy with Insulin

Nov 19, 2019 Insulin Therapy Center, SGLT-2 Therapy Center, Type 1 Diabetes

In regards to pharmacotherapy, patients with type 1 diabetes end up solely relying on insulin therapy for their diabetes management: what if there is an add on option?